A Phase 3 interventional study of Prospekta and Placebo in Post-acute COVID-19 Syndrome, sponsored by Materia Medica Holding. Completed at 32 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-23.
Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial.
The objective of this study is to evaluate the efficacy and safety of Prospekta in the treatment of asthenia in patients after the coronavirus infectious disease (COVID-19).
Design: the multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial.
The study will enroll adult patients of either gender aged 18 to 65 years after new coronavirus infection of 2019 (COVID-19) with symptoms of asthenia that appeared during or after an acute coronavirus infection (COVID-19) and persisting 4 to 12 weeks from the onset of coronavirus infection.
After the patient signs the patient information sheet and the informed consent form for participation in the study, complaints, medical history, physical examination, registration of vital signs are collected, the patient fills in the Fatigue Severity Scale (FSS) and Hospital Anxiety and Depression Scale (HADS). A six-minute walk test (6MWT) is carried out. The physician evaluates the severity of asthenia with FSS scale and records concomitant medications, co-morbidities and concurrent conditions.
If a patient meets all inclusion criteria and does not have any of the exclusion criteria at Visit 1 (Day 1), he/she is randomized to one of two groups: Group 1 - patients receive Prospekta at a dose of 1 tablet twice daily for 4 weeks; Group 2 - patients receive placebo on the study drug regimen.
The trial will use electronic patient diaries (EPD). The patient should record any possible deterioration (if applicable) in the EPD. At Visit 1 (Day 1), the physician will provide guidance on how to work with EPD, so that the patient can use it independently in the future.
At Visit 2 (Week 4 ± 3 days), the physician will collect patient's complaints, record physical examination data and vital signs as well as any changes in concurrent diseases and conditions. The patient fills out the FSS and HADS scales. A 6MWT is carried out. The physician monitors the prescribed treatment and use of concomitant medications, evaluates the safety of the study treatment and patient's compliance, filling out the diary.
The patient stops taking the study drug. At the end of the study treatment period, the patient is monitored for 4 weeks (follow-up period).
At Visit 3 (final visit, Week 8 ± 3 days), the physician collects patient's complaints, records physical examination data and vital signs, changes in concomitant diseases and conditions. The patient fills in the FSS and HADS scales. A 6MWT is carried out. The physician evaluates the safety of the study treatment, checks the completion of the diary.
During the study the patients are allowed to take medications for their chronic conditions, except for medicines listed as "Prohibited concomitant treatment".
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
This study's enrollment of 676 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Browse Post-Acute COVID-19 Syndrome studies →Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablet for oral use. 1 tablet twice daily. The tablets are taken outside of meals (between meals or 15 minutes before eating or drinking), keep the tablets in the mouth, without swallowing, until completely dissolved.
Drug: Prospekta
Tablet for oral use. Placebo using Prospekta scheme.
Drug: Placebo
Oral administration.
Oral administration.
Change in the Mean FSS Score.
Fatigue Severity Scale (FSS). Change in the mean FSS score after 4 weeks of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.
Time frame: after 4 weeks of treatment
Change in Distance of the 6-minute Walk Test.
Change in distance when performing the 6-minute walk test after 4 weeks of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.
Time frame: after 4 weeks of treatment
Change in the Severity of Anxiety on the HADS Subscale.
Hospital Anxiety and Depression Scale (HADS). Change in the severity of anxiety and depression on the HADS subscales after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.
Time frame: after 4 weeks of treatment
Change in the Severity of Depression on the HADS Subscale.
Hospital Anxiety and Depression Scale (HADS). Change in the severity of depression on the HADS subscale after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.
Time frame: after 4 weeks of treatment
Change in the Mean FSS Score Within Follow-up Period.
Change in mean FSS score over 4 weeks of follow-up period at the end of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.
Time frame: after 4 weeks of treatment and after 4 weeks of follow-up at week 8
Change in Distance of the 6-minute Walk Test Within Follow-up Period.
Change in distance when performing the 6-minute walk test over a 4-week follow-up period at the end of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.
Time frame: after 4 weeks of treatment and after 4 weeks of follow-up at week 8
Change in the Severity of Anxiety on the HADS Subscales Within Follow-up Period.
Change in the severity of anxiety on the HADS subscales over a 4-week follow-up period at the end of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.
Time frame: after 4 weeks of treatment and after 4 weeks of follow-up at week 8
Change in the Severity of Depression on the HADS Subscales Within Follow-up Period.
Change in the severity of depression on the HADS subscales over a 4-week follow-up period at the end of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.
Time frame: after 4 weeks of treatment and after 4 weeks of follow-up at week 8
Changes in Vital Signs (Pulse Rate (Heart Rate)).
Based on medical records. Vital signs will be measured in a medical setting.
Time frame: after 4 weeks of treatment and within 4 weeks of the follow-up period at the end of the treatment.
Changes in Vital Signs (Respiration Rate (Breathing Rate)).
Based on medical records. Vital signs will be measured in a medical setting.
Time frame: after 4 weeks of treatment and within 4 weeks of the follow-up period at the end of the treatment (Visit 1: baseline, Visit 2: after 4 weeks of treatment, and Visit 3: after 4 weeks of follow-up at week 8)
Changes in Vital Signs (Blood Pressure).
Based on medical records. Vital signs will be measured in a medical setting.
Time frame: after 4 weeks of treatment and within 4 weeks of the follow-up period at the end of the treatment (Visit 1: baseline, Visit 2: after 4 weeks of treatment, and Visit 3: after 4 weeks of follow-up at week 8).
Presence of Adverse Events (AEs).
The number of participants with adverse events (AEs). Based on medical records.
Time frame: 8 weeks
The Severity of AEs.
The intensity (severity) of adverse events. Based on medical records.
Time frame: 8 weeks
The Outcome of AEs.
The outcome of adverse events. Based on medical records.
Time frame: 8 weeks
AEs Causal Relationship to the Study Drug.
The adverse events causal relationship to the study drug. Based on medical records.
Time frame: 8 weeks
| Milestone | Prospekta | Placebo |
|---|---|---|
| Started | 330 | 346 |
| Completed | 330 | 346 |
| Not completed | 0 | 0 |
Fatigue Severity Scale (FSS). Change in the mean FSS score after 4 weeks of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.
| score on a scale | Prospekta | Placebo |
|---|---|---|
| Baseline | 46.4 ± 6.9 | 45.9 ± 6.6 |
| After 4 weeks | 29.9 ± 9.2 | 31.9 ± 9.9 |
| ∆ between baseline and 4 weeks later | 16.5 ± 9.5 | 14.0 ± 9.4 |
Change in distance when performing the 6-minute walk test after 4 weeks of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.
| meters | Prospekta | Placebo |
|---|---|---|
| Baseline | 426.4 ± 119.2 | 416.9 ± 112.8 |
| After 4 weeks | 457.8 ± 118.2 | 444.7 ± 110.7 |
| ∆ between baseline and 4 weeks later | 31.4 ± 44.5 | 27.8 ± 38.1 |
Hospital Anxiety and Depression Scale (HADS). Change in the severity of anxiety and depression on the HADS subscales after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.
| score on a scale | Prospekta | Placebo |
|---|---|---|
| Baseline | 8.5 ± 4.1 | 8.8 ± 3.9 |
| After 4 weeks | 5.5 ± 3.2 | 6.0 ± 3.3 |
| ∆ between baseline and 4 weeks later | 3.0 ± 3.2 | 2.8 ± 3.1 |
Hospital Anxiety and Depression Scale (HADS). Change in the severity of depression on the HADS subscale after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.
| score on a scale | Prospekta | Placebo |
|---|---|---|
| Baseline | 8.1 ± 3.7 | 8.3 ± 3.8 |
| After 4 weeks | 4.7 ± 2.9 | 5.2 ± 3.0 |
| ∆ between baseline and 4 weeks later | 3.4 ± 3.0 | 3.1 ± 3.1 |
Change in mean FSS score over 4 weeks of follow-up period at the end of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.
| score on a scale | Prospekta | Placebo |
|---|---|---|
| After 4 weeks | 29.9 ± 9.2 | 31.9 ± 9.9 |
| After 8 weeks | 22.9 ± 9.0 | 25.0 ± 10.2 |
| ∆ between value after 4 weeks and after 8 weeks | 7.1 ± 6.3 | 7.0 ± 6.9 |
Change in distance when performing the 6-minute walk test over a 4-week follow-up period at the end of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.
| meter | Prospekta | Placebo |
|---|---|---|
| After 4 weeks | 457.8 ± 118.2 | 444.7 ± 110.7 |
| After 8 weeks | 472.9 ± 116.5 | 462.7 ± 110.1 |
| ∆ between value after 4 weeks and after 8 weeks | 15.9 ± 32.1 | 18.8 ± 32.0 |
Change in the severity of anxiety on the HADS subscales over a 4-week follow-up period at the end of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.
| score on a scale | Prospekta | Placebo |
|---|---|---|
| After 4 weeks | 5.5 ± 3.2 | 6.0 ± 3.3 |
| After 8 weeks | 4.0 ± 2.8 | 4.4 ± 3.0 |
| ∆ between value after 4 weeks and after 8 weeks | 1.5 ± 2.3 | 1.6 ± 2.3 |
Change in the severity of depression on the HADS subscales over a 4-week follow-up period at the end of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.
| score on a scale | Prospekta | Placebo |
|---|---|---|
| After 4 weeks | 4.7 ± 2.9 | 5.2 ± 3.0 |
| After 8 weeks | 3.4 ± 2.6 | 3.7 ± 2.8 |
| ∆ between value after 4 weeks and after 8 weeks | 1.4 ± 2.1 | 1.5 ± 2.1 |
Based on medical records. Vital signs will be measured in a medical setting.
| beats per minute | Prospekta | Placebo |
|---|---|---|
| Visit 1: baseline | 73.0 ± 6.9 | 73.4 ± 6.9 |
| Visit 2: after 4 weeks of treatment | 71.8 ± 5.8 | 71.9 ± 5.6 |
| Visit 3: after 4 weeks of follow-up at week 8 | 71.6 ± 5.3 | 71.4 ± 5.5 |
Based on medical records. Vital signs will be measured in a medical setting.
| breaths per minute | Prospekta | Placebo |
|---|---|---|
| Visit 1 | 16.3 ± 1.3 | 16.4 ± 1.3 |
| Visit 2 | 16.2 ± 1.2 | 16.2 ± 1.2 |
| Visit 3 | 16.2 ± 1.2 | 16.2 ± 1.2 |
Based on medical records. Vital signs will be measured in a medical setting.
| mmHg | Prospekta | Placebo |
|---|---|---|
| SBP/Visit 1 | 121.3 ± 8.6 | 120.9 ± 8.3 |
| SBP/Visit 2 | 121.1 ± 8.4 | 120.6 ± 8.1 |
| SBP/Visit 3 | 121.1 ± 8.2 | 120.4 ± 7.4 |
| DBP/Visit 1 | 75.8 ± 6.5 | 75.8 ± 6.5 |
| DBP/Visit 2 | 75.8 ± 6.3 | 75.9 ± 6.3 |
| DBP/Visit 3 | 76.0 ± 6.1 | 75.4 ± 5.9 |
The number of participants with adverse events (AEs). Based on medical records.
| Participants | Prospekta | Placebo |
|---|---|---|
| Presence of Adverse Events (AEs). | 20 | 20 |
The intensity (severity) of adverse events. Based on medical records.
| number of AEs | Prospekta | Placebo |
|---|---|---|
| Mild | 13 | 15 |
| Moderate | 11 | 13 |
The outcome of adverse events. Based on medical records.
| number of AEs | Prospekta | Placebo |
|---|---|---|
| Recovery/resolution | 22 | 26 |
| No recovery/resolution | 2 | 0 |
| Unknown | 0 | 2 |
The adverse events causal relationship to the study drug. Based on medical records.
| number of AEs | Prospekta | Placebo |
|---|---|---|
| No relation | 20 | 15 |
| Probable | 3 | 4 |
| Possible | 1 | 0 |
| Doubtful | 0 | 9 |
Collected over Reporting of AEs begins after the first dose of IP, continues throughout the study treatment period, and for 4 weeks after the last dose of IP during the follow-up period, up to 8 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prospekta | 0/330 (0%) | 0/330 (0%) | 20/330 (6.1%) |
| Placebo | 0/346 (0%) | 0/346 (0%) | 20/346 (5.8%) |
| Event | Prospekta | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 3/330 | 4/346 |
| DizzinessNervous system disorders | 1/330 | 3/346 |
| Viral infection of the respiratory tractInfections and infestations | 2/330 | 1/346 |
| DrowsinessNervous system disorders | 2/330 | 0/346 |
| Worsening of hypertensionVascular disorders | 2/330 | 0/346 |
| Laboratory confirmed coronavirus infection COVID-19Infections and infestations | 0/330 | 2/346 |
| Epigastric discomfortGastrointestinal disorders | 1/330 | 0/346 |
| Dry mouthGastrointestinal disorders | 1/330 | 0/346 |
| Acute respiratory tract infectionInfections and infestations | 1/330 | 0/346 |
| Acute rhinitisInfections and infestations | 1/330 | 0/346 |
| Age, Continuous(years) | Prospekta | Placebo | Total |
|---|---|---|---|
| Mean | 44.3 ± 12.5 | 42.8 ± 12.6 | 43.5 ± 12.6 |
| Sex: Female, Male(Participants) | Prospekta | Placebo | Total |
|---|---|---|---|
| Female | 216 | 236 | 452 |
| Male | 114 | 110 | 224 |
| Race and Ethnicity Not Collected(Participants) | Prospekta | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Prospekta | Placebo | Total |
|---|---|---|---|
| Russia | 330 | 346 | 676 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2021 to primary completion in Jun 2022, 7 months.
Results were first posted in Sep 2024, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →